At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating CP-690,550, Atorvastatin, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 111 participants across 15 sites in 2 countries.
Detailed Summary
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.
Study Details
Timeline
Interventions
12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily